AIM: To investigate the toxicities, biodistribution and anticancer effect of 5-fluorouracil controlled release implant (5-FUCI) on Walker 256 carcinosarcoma cells in Wistar rats. METHODS: Experiment 1: Wistar rats were randomly divided into three groups (27 rats per group). Blank implant was implanted in left lobe of the liver, and rats were treated with saline solution (in group A) or 5-fluorouracil (subcutaneous injection, group B). 5-FUCI was inserted in left lobe of the liver (group C). The gastrointestinal and hematological toxicities were observed and contents of element F in group C were assayed. Experiment 2: on day 6 after Walker-256 carcinosarcoma transplantation in left lobe of the liver, 5-FUCI was implanted in right lobe of the liver (group E) or left lobe (group F), and rats in control group (group D) were inserted blank implant. Tumor inhibition rate and survival time were investigated. RESULTS: 5-FUCI showed no obvious toxic effect, extraction of Evan's blue from gastrointestinal tissue was normal, the peripheral white blood cells and bone marrow nucleated cells were not reduced, compared with control group (P>0.05). Histological examination revealed that there were no visible changes in small intestinal mucosa, The concentration of 5-fluorouracil in left lobe of the liver was 9.84, 28, 34 times as much as those of right lobe of the liver, heart and kidney respectively after the implantation in group C. They kept a high level of fluorouracil in left lobe of the liver, ranging from (4.414+/-0.482) % to (7.800+/-0.804) %, for eight weeks. Survival days were 28.0+/-2.2, 30.0+/-3.2 and 38.7+/-6.7 d in group D, E and F, respectively. CONCLUSION: 5-FUCI shows no obvious toxicities to gastrointestinal tract and myelotoxicity. After implantation, it kept a high level of 5- fluorouracil in surrounding tissues of the implant for eight weeks. Its antitumor effect on Walker-256 carcinosarcoma is demonstrated.
AIM: To investigate the toxicities, biodistribution and anticancer effect of 5-fluorouracil controlled release implant (5-FUCI) on Walker 256 carcinosarcoma cells in Wistar rats. METHODS: Experiment 1: Wistar rats were randomly divided into three groups (27 rats per group). Blank implant was implanted in left lobe of the liver, and rats were treated with saline solution (in group A) or 5-fluorouracil (subcutaneous injection, group B). 5-FUCI was inserted in left lobe of the liver (group C). The gastrointestinal and hematological toxicities were observed and contents of element F in group C were assayed. Experiment 2: on day 6 after Walker-256 carcinosarcoma transplantation in left lobe of the liver, 5-FUCI was implanted in right lobe of the liver (group E) or left lobe (group F), and rats in control group (group D) were inserted blank implant. Tumor inhibition rate and survival time were investigated. RESULTS:5-FUCI showed no obvious toxic effect, extraction of Evan's blue from gastrointestinal tissue was normal, the peripheral white blood cells and bone marrow nucleated cells were not reduced, compared with control group (P>0.05). Histological examination revealed that there were no visible changes in small intestinal mucosa, The concentration of 5-fluorouracil in left lobe of the liver was 9.84, 28, 34 times as much as those of right lobe of the liver, heart and kidney respectively after the implantation in group C. They kept a high level of fluorouracil in left lobe of the liver, ranging from (4.414+/-0.482) % to (7.800+/-0.804) %, for eight weeks. Survival days were 28.0+/-2.2, 30.0+/-3.2 and 38.7+/-6.7 d in group D, E and F, respectively. CONCLUSION:5-FUCI shows no obvious toxicities to gastrointestinal tract and myelotoxicity. After implantation, it kept a high level of 5- fluorouracil in surrounding tissues of the implant for eight weeks. Its antitumor effect on Walker-256 carcinosarcoma is demonstrated.
Authors: J P Smith; S Kanekal; M B Patawaran; J Y Chen; R E Jones; E K Orenberg; N Y Yu Journal: Cancer Chemother Pharmacol Date: 1999 Impact factor: 3.333
Authors: H P Schlemmer; M Becker; P Bachert; A Dietz; V Rudat; B Vanselow; P Wollensack; I Zuna; M V Knopp; H Weidauer; M Wannenmacher; G van Kaick Journal: Cancer Res Date: 1999-05-15 Impact factor: 12.701
Authors: Ahmed El-Ghannam; Krista Ricci; Ahmed Malkawi; Kiarash Jahed; Kumar Vedantham; Heather Wyan; Lauren D Allen; Didier Dréau Journal: J Mater Sci Mater Med Date: 2010-07-20 Impact factor: 3.896
Authors: Abdelkader E Ashour; Mohammad Badran; Ashok Kumar; Tajamul Hussain; Ibrahim A Alsarra; Alaa Eldeen B Yassin Journal: Int J Nanomedicine Date: 2019-11-28
Authors: Mohammed S Saddik; Mahmoud M A Elsayed; Mohamed Salaheldin A Abdelkader; Mohamed A El-Mokhtar; Jelan A Abdel-Aleem; Ahmed M Abu-Dief; Mostafa F Al-Hakkani; Hatem S Farghaly; Heba A Abou-Taleb Journal: Pharmaceutics Date: 2021-02-06 Impact factor: 6.321
Authors: Ying Dong; Shook-Fong Chin; Elvin Blanco; Erik A Bey; Wareef Kabbani; Xian-Jin Xie; William G Bornmann; David A Boothman; Jinming Gao Journal: Clin Cancer Res Date: 2009-01-01 Impact factor: 13.801